BOTOX Injection Technique for LUTS Due to BPH

This prospective, randomized, comparative study investigated whether combining botulinum toxin type A (Botox) injections in the bladder neck, prostatic urethra, and prostatic parenchyma offers an added clinical benefit compared to injecting the prostatic parenchyma alone. The research was conducted by a team of urologists including Mohamed Aboulfotouh El Gharably, Helmy Ahmed Eldib, Ahmed Ebrahim Zahran, Mahmoud Farag, Hazem Mohamed Ali, and Yahia Elkerdasy. The study focused on patients with benign prostatic hyperplasia (BPH) presenting with a prostate size between 30 and 60 grams. The clinical rationale behind utilizing Botox is its ability to obstruct the release of acetylcholine at neuromuscular junctions, which relaxes the smooth muscle surrounding the bladder neck and prostate stroma while inducing apoptosis in prostatic parenchymal cells to reduce the overall prostate volume.

The methodology involved sixty male participants who experienced persistent moderate lower urinary tract symptoms (LUTS) and a low maximum urinary flow rate (Qmax) despite undergoing six months of medical treatment. To qualify for the trial, patients needed to have an International Prostate Symptom Score (IPSS) greater than 12, a Qmax below 15 mL/second, and a prostate volume of 30 to 60 grams, while individuals with urethral strictures, neurogenic voiding disorders, or high post-void residual volumes over 250 mL were excluded. The sixty patients were evenly randomized into two cohorts of thirty using an opaque sealed envelope technique. Group A received a cystoscopic injection of 200 units of Botox divided across the prostatic parenchyma, bladder neck, and prostatic urethra, whereas Group B received the same dose exclusively within the prostatic parenchyma. Both procedures were performed under intravenous general anesthesia, and patients discontinued their standard LUTS medications following the injections.

Post-operative outcomes were tracked during a six-month follow-up period with key evaluations scheduled at one, three, and six months. The statistical findings demonstrated that Group A achieved a significantly greater reduction in prostate volume compared to Group B from the one-month mark onward, an improvement that stabilized between the third and sixth months. Additionally, Group A demonstrated a significantly lower post-void residual volume (PVRV) and a significantly higher Qmax value than Group B starting at one month and persisting through the entire six-month duration. Symptom severity, measured via IPSS, showed that both groups improved over time, but Group A exhibited significantly lower IPSS scores than Group B from one month onward, with the most substantial enhancements occurring within the first three months.

The study concluded that the combined Botox injection technique delivers superior clinical outcomes compared to injecting the prostatic parenchyma alone, driven by its simultaneous action on both the static glandular tissue and dynamic smooth muscle components of the prostate. The authors highlighted certain limitations of their trial, such as the absence of a third placebo control group to validate the results against a potential placebo effect. They recommended that future multi-center studies feature extended follow-up periods and compare different injection approaches, such as trans-perineal, trans-rectal, and transurethral routes, to reach a definitive consensus on standardized inclusion criteria and injection techniques for treating BPH with botulinum toxin.

Inclusion criteria

Male patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) Moderate symptoms, defined as International Prostate Symptom Score (IPSS) > 12 Maximum urinary flow rate (Qmax) < 15 mL/second Prostate volume between 30 and 60 grams Persistent symptoms after at least 6 months of medical therapy for BPH Ability to provide informed consent

Exclusion criteria

story of chronic bladder catheterization Compromised cardiopulmonary status Contraindications to botulinum toxin type A (BoNT-A) Current urinary tract infection Neurogenic voiding dysfunction Post-void residual (PVR) > 250 mL History of previous prostatic surgery Prostatitis Urethral strictur